Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 95%
filed 2026-06-11
Item 1.01
Vireo Growth Inc. acquired 100% of the Partnership Interests in Agribusiness Holdings (which indirectly provides 100% ownership of Bridgewell) on June 5, 2026, for approximately US$13.66 million in convertible subordinated notes. The acquisition was funded through issuance of convertible promissory notes and included assumption of approximately $30.35 million in existing indebtedness, materially affecting the registrant's assets, capital structure, and business scope.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 3.02
Vireo Growth Inc. issued convertible subordinated notes and subordinate voting shares issuable upon conversion in a private placement exempt under Section 4(a)(2) and Regulation D. The convertible securities will result in equity dilution upon conversion, materially affecting investor assessment of ownership and capital structure.
View raw filing on EDGAR →
RH
(RH)
8-K
Earnings release
confidence 98%
filed 2026-06-11
Item 2.02
RH disclosed financial results for the first quarter ended May 2, 2026 via a press release and shareholder letter on June 11, 2026. This is a standard quarterly earnings release disclosed under Item 2.02, with exhibits attached containing the formal announcement and letter to shareholders. Quarterly financial results are material to investors' assessment of the registrant's performance and financial condition.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 1.01
AECOM entered into a $500 million revolving credit facility with Bank of America on June 10, 2026, secured with leverage covenants including a 4.00x consolidated leverage ratio. This material financing arrangement affects the company's liquidity, financial flexibility, and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Shake Shack's annual meeting of stockholders held on June 10, 2026. The filing presents voting results for three proposals: election of two Class II directors (Robert Lynch and Tristan Walker), ratification of Ernst & Young LLP as independent auditor, and an advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Organon & Co. held its 2026 Annual Meeting of Stockholders on June 9, 2026, with voting results disclosed for four proposals: election of ten directors, advisory vote on named executive officer compensation, approval of an amended 2021 Incentive Stock Plan increasing authorized shares by 8,000,000, and ratification of PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-11
Item 5.02
Paul F. De Cock was appointed Chief Executive Officer and Director of Mohawk Industries, effective September 30, 2026, succeeding retiring CEO Jeffrey S. Lorberbaum. The appointment includes a base salary of $1,267,000, bonus structure, and an equity award of 30,000 RSUs, representing a material executive transition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the results of Fortive Corporation's June 9, 2026 annual shareholder meeting, including voting outcomes on three proposals: election of eight directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each director nominee and proposal are the core content, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 discloses the results of Vertex's Annual Meeting of Stockholders held on June 10, 2026, including the election of three directors (Eric Andersen, David DeStefano, and Christopher Young) and the ratification of Crowe LLP as independent auditor, with specific vote tallies for each matter. The disclosure directly matches the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-11
Item 5.02
The filing discloses the election of Tiffany To as a member of the Board of Directors on June 5, 2026. While the disclosure includes compensation details (annual base retainer of $107,500 and a one-time equity grant of $177,500 in restricted stock units), the principal action is the appointment of a new director to the Board. This is a material event affecting the composition of the company's governance and is appropriately classified as an executive appointment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Humacyte entered into an underwriting agreement on June 10, 2026 to issue and sell 47,619,048 shares of common stock at $1.05 per share in a registered public offering, with a 30-day option for up to an additional 7,142,857 shares. The offering is expected to raise approximately $46.80 million (or $53.85 million with full option exercise), representing a substantial dilutive issuance to existing shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the results of Light & Wonder's June 10, 2026 annual stockholder meeting, including voting tallies for five proposals: election of nine directors, advisory approval of named executive officer compensation, approval of director-CEO equity grants under ASX Listing Rule 10.14, approval of non-employee director compensation limits under ASX Listing Rule 10.17, and ratification of Deloitte & Touche LLP as independent auditor. The detailed voting results (For/Against/Abstain/Broker Non-Votes) for each proposal are the core disclosure, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-06-11
Item 8.01
Innovative Industrial Properties announced a $402.5 million private offering of exchangeable senior notes due 2029 with an initial exchange rate of 14.4113 shares per $1,000 principal amount, along with concurrent ATM offerings of 680,842 common shares and 948,034 preferred shares, creating material dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Ocugen held its Annual Meeting of Stockholders on June 11, 2026, with shareholders voting on four proposals: election of two Class III directors (Kirsten Castillo and Satish Chandran), ratification of PricewaterhouseCoopers LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on the frequency of future compensation votes. Final vote tallies including For, Against, Abstentions, and Broker Non-Votes were disclosed for each proposal.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-11
Item 8.01
Mohamed Genead, M.D., M.Sc., was appointed as Chief Medical Officer of Ocugen effective June 11, 2026, following his service as Acting/Interim Chief Medical Officer since May 8, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 8.01
The Company entered into forward sale agreements on June 9, 2026, relating to the offer and sale of 9,000,000 common shares (plus up to 1,350,000 additional shares under an underwriter option), with expected net proceeds of approximately $195.6 million (or $225.0 million if the option is exercised in full). This is a material dilutive equity issuance that will increase share count and is expected to raise substantial capital for acquisitions and general corporate purposes. The forward sale structure and the magnitude of the offering make this a material event affecting shareholder equity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-11
Item 8.01
This Item 8.01 discloses the results of exchange offers and consent solicitations for Qorvo Notes in connection with proposed merger transactions between Skyworks and Qorvo. The filing explicitly references "the Mergers" and notes that Skyworks has filed a Form S-4 registration statement for the merger. While the immediate disclosure concerns debt exchange offers, the context makes clear this is part of a material acquisition/merger activity, which is the principal event driving the disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Qualys held its annual meeting of stockholders on June 10, 2026, at which shareholders voted on four proposals: election of three Class II directors (Bradford L. Brooks, Wendy M. Pfeiffer, and John A. Zangardi), ratification of Grant Thornton LLP as independent auditor, advisory approval of executive compensation, and approval of the amended 2012 Equity Incentive Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes for three proposals: election of ten directors to the Board, ratification of KPMG LLP as independent auditors, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure that affects investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
OraSure announced FDA clearance of its Colli-Pee™ Dx Urine Collection Kit for use with Roche molecular diagnostic systems to detect four sexually transmitted infections. This is a material regulatory milestone that expands the company's product portfolio and market reach through a partnership with a major diagnostics company (Roche), but does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or litigation). The disclosure warrants classification as a material product/regulatory event under "other_material."
View raw filing on EDGAR →
8-K
M&A activity
confidence 72%
filed 2026-06-11
Item 1.01
Prairie Operating Co. entered into two material definitive agreements on June 10, 2026: a Second Amendment to its credit facility reaffirming a $475 million borrowing base with modified covenants and redetermination procedures, and a Letter Agreement with Hudson Bay PH XIX LLC permitting conversion of Series F Preferred Stock into up to 21.2 million additional common shares with adjusted warrant issuance percentages. These agreements represent material changes to the company's capital structure, financial obligations, and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 8.01
The filing discloses a private offering of Exchangeable Senior Notes due 2031 priced at 3.50%, issued to qualified institutional buyers under Rule 144A. Exchangeable notes are convertible into the company's common stock, making this a dilutive issuance. The pricing announcement on June 11, 2026 represents a material capital-raising event that would affect investor assessment of share dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-11
Item 2.01
KalVista Pharmaceuticals completed a merger with a Parent entity on June 11, 2026, resulting in a change of control. The transaction included a tender offer and modification of convertible note terms to provide cash conversion rights at $27.00 per share, with the Parent acquiring control of the Company effective at the Effective Time.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-11
Item 3.01
Following completion of the merger, KalVista notified Nasdaq on June 10–11, 2026 of the consummation and requested delisting of its shares from The Nasdaq Global Market. Trading was halted effective June 10, 2026 and ceased on June 11, 2026, with the Company intending to file Form 25 and Form 15 to remove listing and terminate SEC registration.
View raw filing on EDGAR →
8-K
Exec departure
confidence 65%
filed 2026-06-11
Item 5.02
Eight directors (Brian J. G. Pereira, Benjamin L. Palleiko, William Fairey, Laurence Reid, Bethany Sensenig, Nancy Stuart, Patrick Treanor, and Edward W. Unkart) resigned from the Company's board and all committees effective immediately in connection with the merger consummation, with no disagreement cited.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-11
Item 2.03
The filing discloses creation of a direct financial obligation under Item 2.03, incorporating Item 1.01 by reference; the specific nature of the obligation (debt, lease, contingent liability, or other commitment) cannot be determined without access to the referenced Item 1.01 content.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-11
Item 3.03
Item 3.03 discloses a material modification to rights of security holders, incorporating by reference Items 3.01, 5.01, and 5.03; the specific nature of the modification cannot be reliably determined from the cross-references alone, though it likely relates to the merger, delisting, or change of control.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-06-11
Item 5.02
Ms. Jehna Silva was appointed as a director of Farmers & Merchants Bancorp effective June 8, 2026, and assigned to three board committees (CRA, Budget and Finance, and ALCO). The appointment is material due to its impact on board composition and governance structure, and notably involves a family relationship with CEO Kent Steinwert that is relevant to investors assessing board independence.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-11
Item 4.01
Item 4.01 discloses the dismissal of Beckles & Co., Inc. as independent registered public accounting firm on June 8, 2026, and the appointment of Dylan Floyd Accounting & Consulting as the new auditor on June 10, 2026. This is a classic auditor change event. The filing explicitly states no disagreements existed between the registrant and the dismissed auditor, and no prior consultations occurred with the new auditor, indicating a routine transition rather than a dispute-driven change.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-11
Item 2.02
Item 2.02 discloses the issuance of a press release on June 11, 2026 regarding results of operations and financial condition. This is a standard earnings release disclosure, typically material to investors as it communicates the registrant's financial performance and results.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 1.01
Edesa Biotech entered into a Securities Purchase Agreement on June 10, 2026, for a private placement of 729,241 common shares at $4.69–$5.21 per share, raising approximately $3.5 million. This unregistered equity issuance materially dilutes existing shareholders' ownership and increases the company's share count.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Compass Therapeutics' Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for four proposals: election of two Class III directors (Schuetz and Lindahl), ratification of CohnReznick LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote frequency on compensation. The detailed vote tallies (For/Against/Withheld/Broker Non-votes) for each proposal are the core content of this 8-K section.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
VSee Health entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. on June 2, 2026, granting the investor the right to purchase up to $10 million of common stock over three years at 97% of the lowest daily VWAP, with an Exchange Cap of approximately 19.99% of outstanding shares and immediate issuance of 532,481 commitment shares. The unregistered private placement relies on Section 4(a)(2) exemption and materially dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 80%
filed 2026-06-11
Item 3.02
VSee Health entered into a securities purchase agreement on June 8, 2026, issuing a secured promissory note for $271,739.13 principal at 18% annual interest due December 8, 2026, in an unregistered transaction exempt under Section 4(a)(2) of the Securities Act and/or Regulation D. The transaction represents a material financing arrangement with a security interest in company assets and mandatory repayment upon equity financing receipt, indicating significant financial stress.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
Shoe Carnival Inc held its 2026 Annual Meeting of Shareholders on June 10, 2026, with shareholder approval of director elections (Diane E. Randolph and J. Wayne Weaver), an advisory compensation vote, auditor ratification (Deloitte & Touche LLP), and a material amendment to change the company's legal name to Shoe Station Group, Inc., effective June 12, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-11
Item 7.01
Dana announced a proposed combination with Eaton Corporation's Vehicle and eMobility business segments, with Dana to merge with a SpinCo entity created from Eaton's separation. This constitutes entry into a material acquisition/merger transaction. The disclosure explicitly references the "Proposed Combination" and describes the transaction structure involving exchange offers and merger, which are hallmark M&A activities requiring 8-K disclosure under Item 1.01 or 2.01, though filed here under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Orthofix Medical Inc. held its Annual Meeting of Shareholders on June 10, 2026, with voting results disclosed on four matters: election of ten directors, advisory approval of executive compensation, ratification of Ernst & Young LLP as auditor, and approval of Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan increasing available shares by 1,250,000.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the results of the Annual Meeting of Stockholders held on June 10, 2026, including voting outcomes for two proposals: election of two Class II directors (Rainer Erdtmann and Eric Aguiar) and ratification of Deloitte & Touche LLP as independent auditor. The filing provides detailed vote counts (for, against, abstentions, and broker non-votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
This disclosure announces initial Phase 1b clinical trial data for budoprutug in primary ITP, showing favorable safety and efficacy signals (90% B-cell depletion, platelet responses in 4/6 patients at 250 mg dose, no serious adverse events). While clinical trial progress is material to a biotech company's valuation and investor assessment, it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M&A activity, restatement, or other defined categories). The data supports continued development and is clearly significant to investors, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
Silence Therapeutics disclosed Phase 1 clinical trial data for divesiran (SANRECO study) presented at the EHA 2026 Annual Congress. While this is a clinical development update rather than a traditional earnings release or defined material event, the presentation of follow-up and quality-of-life data from a first-in-class siRNA therapy in a rare disease indication (polycythemia vera) would be material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into earnings_release, material_litigation, or other specific categories, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 1.01
Atossa Therapeutics entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants at $3.30 per share, expected to raise approximately $4.1 million in net proceeds. While technically registered (via Form S-3), this is a direct offering to institutional investors with significant warrant dilution (up to 2.7 million additional shares if warrants are exercised), representing material equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-11
Item 8.01
Enliven Therapeutics announced updated positive Phase 1 clinical trial data from the ENABLE trial evaluating ELVN-001 in patients with chronic myeloid leukemia, including key outcomes from an FDA End-of-Phase 1 meeting and selection of the 80 mg QD dose for Phase 3 development. This represents material clinical progress for the company's lead candidate that affects investor assessment of the pipeline and regulatory pathway.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Shattuck Labs entered into an underwriting agreement on June 9, 2026 for a registered public offering of 10.9 million shares of common stock at $4.00 per share, plus 7.9 million pre-funded warrants, with underwriters exercising a full 30-day overallotment option for an additional 2.8 million shares. This is a material dilutive equity issuance that raises capital through the sale of common stock and warrant securities, affecting existing shareholders' ownership percentages and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Jaguar Health entered into two material equity financing arrangements on June 9, 2026: a $40 million Equity Line of Credit (ELOC) with an accredited investor and a $2 million Preferred Stock Financing with multiple investors including pre-funded warrants. Both transactions involve unregistered or to-be-registered equity issuances that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 5.03
The company filed a Series P Certificate of Designation establishing the terms of a new preferred stock class with 8% annual dividends, liquidation preferences, mandatory and optional redemption provisions, and anti-dilution protections. These structural provisions create contingent obligations that could materially affect the company's capital structure and shareholder value.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Broadcom announced the launch of cash tender offers for certain debt securities on June 11, 2026. While this is a material capital management activity that would affect investor assessment of the company's financial strategy and debt structure, it does not fit neatly into the more specific event categories (it is not a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, or dilutive equity issuance). Debt tender offers are material refinancing activities but lack a dedicated taxonomy category, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—it describes the mechanism and structure of consolidated obligations rather than disclosing a specific new debt issuance event. The prose emphasizes that Schedule A lists obligations "committed to be issued" and notes the FHLBank has not made materiality judgments on particular obligations. This appears to be a standing disclosure of the FHLBank's debt issuance framework rather than a discrete material event triggering Item 2.03, making it best classified as other_material rather than a more specific event type.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 3.02
The Company disclosed the sale of 12,690 Class D Common Shares for $350,000 gross proceeds on June 8, 2026, as part of a continuous private placement offering of up to $2.165 billion in common shares under Section 4(a)(2) and Regulation D Rule 506(c). This is a classic unregistered equity issuance that creates dilution to existing shareholders and is material to investors assessing the registrant's capital structure and future equity dilution risk.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-11
Item 5.02
The filing discloses the appointment of Kevin J. Necas, Jr. as Senior Vice President – Chief Accounting Officer and principal accounting officer effective July 2, 2026. While Michael P. Gallagher's retirement is also mentioned, the principal disclosed action centers on the appointment of Necas to a key financial officer role. The appointment of a principal accounting officer is material to investors as it affects the registrant's financial reporting oversight and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from Airgain's 2026 Annual Meeting held on June 10, 2026. The filing reports final vote tallies for four proposals: election of two Class I directors (Sims and Chung), ratification of Grant Thornton LLP as auditor, advisory approval of named executive officer compensation, and approval of the amended 2016 Incentive Award Plan. All proposals passed. This is a quintessential Item 5.07 shareholder vote results disclosure, material to investors as it confirms governance and compensation decisions.
View raw filing on EDGAR →